問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Family Medicine

更新時間：2023-09-19

吳晉祥Wu, Jin-Shang
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳晉祥

List

10Cases

2006-02-01 - 2007-06-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2019-10-15 - 2021-06-01

Phase II

Completed
A 16-Week, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily PF-06882961 Administration in Adults with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or Diet and Exercise.

  • Condition/Disease

    Diabetes Mellitus, Type 2

  • Test Drug

    PF-06882961

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2019-12-01 - 2031-12-31

Phase III

Active
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the Prevention of Oral Persistent Infection With HPV Types 16, 18, 31, 33, 45, 52, or 58 in Adult Males, 20 to 45 Years of Age

  • Condition/Disease

    Human Papillomavirus oral Infections

  • Test Drug

    GARDASIL 9 (V503)

Participate Sites
4Sites

Recruiting4Sites

2009-01-01 - 2010-06-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-06-01 - 2016-08-31

Phase III

A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

  • Condition/Disease

    Treatment of Type 2 Diabetes Mellitus (T2DM)

  • Test Drug

    Ertugliflozin

Participate Sites
5Sites

Terminated5Sites

2012-06-15 - 2013-06-15

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2010-11-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-04-01 - 2014-04-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-12-08 - 2023-02-01

Phase III

A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age

  • Condition/Disease

    Type 2 Diabetes Mellitus in Pediatric Patients

  • Test Drug

    Dapagliflozin / Saxagliptin

Participate Sites
3Sites

Recruiting2Sites

Suspended1Sites

牛道明
Taipei Veterans General Hospital

2020-01-01 - 2024-08-08

Phase III

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

  • Condition/Disease

    Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities

  • Test Drug

    Tirzepatide

Participate Sites
5Sites

Terminated5Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB